Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 585 participants.
Also called NCT01697592
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 585 participants
- Sponsor
- Registry
-
NCT01697592
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01697592. Randomized; triple masking; primary purpose treatment. Start 2012-10-24 (actual); primary completion 2014-05-08 (actual). Results posted on 2015-10-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Omarigliptin
- Intervention (Drug)
- Matching placebo to omarigliptin
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01697592- Content hash
06f2810b2bdecfa04f1c23e4f47470aeb4cbcd88c0deb621b1eb41c9c40b825f